By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GTx, Inc. 

3 N. Dunlap Avenue, Third Floor

Memphis  Tennessee  38163  U.S.A.
Phone: 901-523-9700 Fax: 901-523-9772



Company News
GTx, Inc. (GTXI) Snags $48.5 Million 9/26/2017 5:48:42 AM
GTx, Inc. (GTXI) Announces Positive Preliminary Results From Ongoing Phase II Proof-Of-Concept Clinical Trial In Women With Stress Urinary Incontinence 6/12/2017 7:43:53 AM
GTx, Inc. (GTXI) Announces Acceptance Of An Abstract On Preliminary Results From Phase II Clinical Trial In Women With Stress Urinary Incontinence At The International Continence Society Annual Meeting 5/11/2017 6:43:28 AM
GTx, Inc. (GTXI) Announces Results From Preclinical Studies Of Sarms In Duchenne Muscular Dystrophy Models Published In Human Molecular Genetics 5/3/2017 6:43:34 AM
GTx, Inc. (GTXI) Provides Corporate Update And Reports Fourth Quarter And Year-End 2016 Financial Results 3/15/2017 7:14:20 AM
GTx, Inc. (GTXI) To Report Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017 3/7/2017 6:24:36 AM
GTx, Inc. (GTXI) Announces 1-for-10 Reverse Stock Split 12/5/2016 11:26:21 AM
GTx, Inc. (GTXI) Release: Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer 11/28/2016 12:40:44 PM
GTx, Inc. (GTXI) Provides Corporate Update and Reports Third Quarter 2016 Financial Results 11/3/2016 12:02:43 PM
GTx, Inc. (GTXI) Achieves Stage 1 Milestone In Phase II Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer 9/8/2016 11:31:46 AM